Amanda Peyser
Nurse Practitioner · New York, NYNPI 1902273741
Payments from drug & device makers
Across 94 payments — averaging $45.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- QOL Medical, LLC$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$462
- Ardelyx, Inc.$217
- Ferring Pharmaceuticals Inc.$137
- Takeda Pharmaceuticals U.S.A., Inc.$130
- Bristol Myers Squibb$95
- plus $590 from 16 others
What the payments were for
- Speaking & faculty fees$2,00047%
- Travel & lodging$52112%
- Food & beverage$1,77441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| QOL Medical, LLC | 10 | $2,665 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $462 |
| Ardelyx, Inc. | 10 | $217 |
| Ferring Pharmaceuticals Inc. | 3 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $130 |
| Bristol Myers Squibb | 4 | $95 |
| AbbVie | 4 | $89 |
| Sanofi | 3 | $87 |
| Exact Sciences | 3 | $71 |
| Johnson & Johnson | 2 | $53 |
| Merck | 3 | $52 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Intercept Pharmaceuticals, Inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Evoke Pharma, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Amgen | 1 | $18 |
| Celltrion USA Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,296 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 17 | $45,417 |
| LinzessLinaclotide | 44 | $41,388 |
| CreonLipase/Protease/Amylase | 20 | $40,208 |
| MotegrityPrucalopride Succinate | 22 | $19,836 |
| TrulancePlecanatide | 18 | $13,171 |
| Dexlansoprazole DrDexlansoprazole | 13 | $5,605 |
| Pantoprazole Sodium | 215 | $3,982 |
| Budesonide EcBudesonide | 14 | $2,335 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 15 | $2,020 |
| Famotidine | 80 | $1,845 |
| Sucralfate | 24 | $1,213 |
| Omeprazole | 120 | $1,203 |
| Dicyclomine Hcl | 38 | $765 |
| Budesonide DrBudesonide | 12 | $539 |
| Ondansetron OdtOndansetron | 19 | $343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $89 | $81,59664 claims |
| Aimmune Therapeutics, Inc.Zenpep | $24 | $45,41717 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $130 | $19,83622 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu | $462 | $15,19133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in New York
- Patricia McGoldrickNew York$202K
- Jodi LogerfoNew York$48K
- Aileen FerrickNew York$26K
- Tsz Isabel WongNew York$25K
- Chris BustamanteNew York$22K
- Mayra PozoNew York$14K
- Janet JohnsonNew York$12K
- Rachel RankinNew York$10K
- Richelle CassellNew York$10K
- Michelle DartSyracuse$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.